Glucotrack, OneTwo Analytics AB seek to 'revolutionize’ diabetes management 

RUTHERFORD, N.J., and STOCKHOLM – A new agreement with OneTwo Analytics AB will allow Glucotrack to leverage next-generation artificial intelligence and machine learning-based analytics to evaluate clinical study data from its continuous blood glucose monitors. “OneTwo Analytics are experts in simplifying complex diabetes data to generate simple, clear insights empowering clinics, health care professionals, and individuals with diabetes to make better informed decisions,” said Paul V. Goode, PhD, president and CEO of Glucotrack. “We are excited to leverage their substantial analytics experience to identify, assess and quantify the potential long-term benefits of the CBGM technology. We are committed to building on our robust suite of preclinical and in silico data by utilizing their comprehensive analytical and AI assessment tools, thereby ensuring our ability to deliver a disruptive, high-quality glucose monitoring solution to people with diabetes.” The CBGM, a long-term implantable device with no on-body external component, is designed to provide three years of continuous, accurate blood glucose monitoring. The companies say the partnership will help to develop a “truly end-to-end solution” for both health care providers and patients. “We are excited to expand our efforts through the development of a comprehensive ecosystem that combines blood glucose insights, risk stratification data, patient engagement tools, and actionable clinical dashboards,” said Steven Pusterla, chief commercial officer of OneTwo Analytics. “Together, we aim to revolutionize diabetes management and improve care for the millions of people navigating life with diabetes every day.”